诺禾致源NOVOGENE品牌怎么样 申请店铺

我要投票 诺禾致源NOVOGENE在医疗器械行业中的票数:648 更新时间:2026-01-28
诺禾致源NOVOGENE是哪个国家的品牌?「诺禾致源NOVOGENE」是 北京诺禾致源科技股份有限公司 旗下著名品牌。该品牌发源于北京,由创始人李瑞强在2011-03-15期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

外推网助力诺禾致源NOVOGENE品牌出海!将品牌入驻外推网,定制诺禾致源NOVOGENE品牌推广信息,可以显著提高诺禾致源NOVOGENE产品曝光,简直是跨境电商爆单神器!目前仅需1000元/年哦~

诺禾致源NOVOGENE怎么样

北京诺禾致源科技股份有限公司于2011年3月在北京中关村生命科学园注册成立,专注于开拓前沿分子生物学技术和高性能计算在生命科学研究和人类健康领域的应用,致力于成为全球领先的基因组学产品和服务提供者。企业总部位于北京,在天津、南京、美国和新加坡设有实验室或实验基地,并在香港、美国和英国设有子公司,办公面积逾26'000m2。

诺禾致源目前已经成为全球较大测序服务中心,每年可完成200'000人全基因组测序的超高通量。诺禾致源引入的测序平台包括10台PacBioSequel、25台HiSeqX、10台HiSeq2000/2500、4台MiSeq、1台HiSeq4000、4台NextSeq500和6台LifeIonProton(DA8600);而全球领先的高性能计算平台和数据中心运算能力达到了878Tflops,总内存368TB,总存储26.8PB,有效地支撑着生命科学研究和医疗健康两大领域对大数据分析和存储的需求。

目前,诺禾致源现已建立一支来自海内外顶级名校、多学科交叉型的高素质综合团队,其中硕士及其以上学历占比近68%。以创始人李瑞强博士为首建立的生物信息学专业分析团队以技术产品开发为导向,在分子病理学、肿瘤诊治和遗传病检测及大数据整合等多个层面积累了丰富的经验。

诺禾致源的业务覆盖科技服务、肿瘤基因检测及遗传检测等领域,为全球研究型大学、科研院所、医院、医药研发企业、农业企业等提供基因测序和生物信息技术支持等服务。肿瘤检测依托完整的分子病理检测平台,面向患者、医院和药企提供精准的实体瘤分子病理检测产品与服务,以深度基因测序和大数据分析解读为核心,持续开发国际领先的肿瘤基因检测产品,提供肿瘤用药指导、动态监测、肿瘤遗传易感基因检测等肿瘤精准治疗解决方案。在遗传检测方面诺禾致源已开发一系列基于二代测序技术的检测服务,包括孕前基因检测,新生儿基因筛查,个人基因组等产品,致力于开拓基因组学在人类健康领域的应用,专注于生殖健康和个人基因组领域,并为客户提供专业的遗传咨询服务。


Beijing Nuohe Zhiyuan Technology Co., Ltd. was registered and established in Zhongguancun Life Science Park in March 2011. It focuses on exploring the application of cutting-edge molecular biology technology and high-performance computing in the field of life science research and human health, and is committed to becoming a leading global provider of genomic products and services. Headquartered in Beijing, the company has laboratories or experimental bases in Tianjin, Nanjing, the United States and Singapore, and subsidiaries in Hong Kong, the United States and the United Kingdom, with an office area of more than 26'000m2. At present, Nuohe Zhiyuan has become the largest sequencing service center in the world, which can complete the ultra-high throughput sequencing of the whole genome of 200'000 people every year. The sequencing platform introduced by Nuohe Zhiyuan includes 10 pacbiosequels, 25 hiseqx, 10 hiseq2000 / 2500, 4 miseq, 1 hiseq4000, 4 nextseq500 and 6 lifeionproton (da8600); the world's leading high-performance computing platform and data center have computing power of 878tflops, total memory of 368tb, total storage of 26.8pb, which effectively supports life science research and medical health The demand of big data analysis and storage in large fields. At present, Nuohe Zhiyuan has established a high-quality comprehensive team from top universities at home and abroad, with a master's degree or above accounting for nearly 68%. The bioinformatics professional analysis team, led by the founder Dr. Li Ruiqiang, has accumulated rich experience in molecular pathology, tumor diagnosis and treatment, genetic disease detection, big data integration and many other layers, guided by technical product development. Nuohe Zhiyuan's business covers science and technology services, tumor gene detection, genetic detection and other fields, providing gene sequencing and bio information technology support services for global research universities, scientific research institutes, hospitals, pharmaceutical R & D enterprises, agricultural enterprises, etc. Tumor detection relies on a complete molecular pathology detection platform to provide patients, hospitals and pharmaceutical companies with accurate solid tumor molecular pathology detection products and services. With in-depth gene sequencing and big data analysis and interpretation as the core, it continues to develop internationally leading tumor gene detection products, providing tumor medication guidance, dynamic monitoring, tumor genetic susceptibility gene detection and other tumor precise treatment Solution. In terms of genetic testing, Nuohe Zhiyuan has developed a series of testing services based on second-generation sequencing technology, including pre pregnancy gene testing, newborn gene screening, personal genome and other products, committed to exploring the application of genomics in the field of human health, focusing on the field of reproductive health and personal genome, and providing professional genetic consulting services for customers.

本文链接: https://brand.waitui.com/d899c7460.html 联系电话:请联系客服添加 联系邮箱:请联系客服添加

外推网广告位招租,每天只要9块9

7×24h 快讯

2连板天奇股份:天奇银河的具身智能机器人相关业务尚处于市场开拓阶段,对公司2025年业绩情况影响较小

36氪获悉,天奇股份公告,公司股票于2026年1月26日、1月27日连续两个交易日内收盘价格涨幅偏离值累计达到21.99%,属于股票交易异常波动的情况。公司与银河通用机器人于2025年5月成立合资公司天奇银河。目前,天奇银河已开展具身智能机器人在汽车产业链、3C制造等典型工业制造场景落地应用相关业务。上述业务尚处于市场开拓阶段,天奇银河的经营情况对公司2025年业绩情况影响较小,对公司未来年度业绩影响存在不确定性。请广大投资者注意投资风险。

36分钟前

中国黄金:主要从事黄金珠宝首饰研发、加工、零售、批发及回购等,未拥有探矿权、采矿权

36氪获悉, 中国黄金公告,公司股票交易存在市场情绪过热情形,可能存在短期涨幅较大后的下跌风险。公司主营业务未发生变化,主要从事黄金珠宝首饰研发、加工、零售、批发及回购等,未拥有探矿权、采矿权,敬请广大消费者理性决策,审慎投资。

36分钟前

波音2025年第四季度营收239.48亿美元,同比增长57%

1月27日,波音公布2025年第四季度财报显示,营收239.48亿美元,同比增长57%;按GAAP计算,净利润82.20亿美元,去年同期为亏损38.61亿美元;调整后每股收益10.23美元,去年同期为亏损5.46美元。(界面)

36分钟前

美股大型科技股盘前普涨,英特尔涨超3%

36氪获悉,美股大型科技股盘前普涨,截至发稿,英特尔涨超3%,苹果、谷歌涨超1%,微软涨0.66%,亚马逊涨0.51%,特斯拉涨0.42%,英伟达涨0.39%,Meta涨0.23%。

36分钟前

热门中概股美股盘前多数上涨,哔哩哔哩涨超4%

36氪获悉,热门中概股美股盘前多数上涨,截至发稿,哔哩哔哩涨超4%,百度涨超2%,阿里巴巴涨超1%,蔚来涨0.65%,小鹏汽车涨0.59%,拼多多涨0.36%;京东、爱奇艺跌超1%,理想汽车跌0.94%。

36分钟前

本页详细列出关于诺禾致源NOVOGENE的品牌信息,含品牌所属公司介绍,诺禾致源NOVOGENE所处行业的品牌地位及优势。
咨询